Search
ENTR-601-44
go.drugbank.com/drugs/DB17836InvestigationalDeveloped by Entrada Therapeutics, it was investigated for the treatment of Duchenne muscular dystrophy.[L46641]
PAS-004
go.drugbank.com/drugs/DB18611InvestigationalPAS-004 is an allosteric MEK 1/2 inhibitor being developed by Pasithea Therapeutics. It is being investigated for the treatment of neurofibromatosis 1 and Noonan syndrome.
Tranilast
go.drugbank.com/drugs/DB07615InvestigationalTranilast is an antiallergic drug developed by Kissei Pharmaceuticals. In 1982, it was approved in Japan and South Korea for the management of bronchial asthma.
Categories: Analgesics, Non-NarcoticSynonyms: N-(3,4-Dimethoxycinnamoyl)anthranilic acidDiaminopyrimidine oxide
go.drugbank.com/drugs/DB18756ApprovedDiaminopyrimidine oxide is a compound similar to [minoxidil] which is used to aid in hair growth.
Synonyms: 2,4-diaminopyrimidine 3-n-oxideTaliglucerase alfa
go.drugbank.com/drugs/DB08876ApprovedTaliglucerase alfa is the recombinant active form of the human lysosomal enzyme, β-glucocerebrosidase. It was approved in 2012 and is marketed under the name Elelyso for use in patients with type 1 Gaucher's disease.
Ixmyelocel-T
go.drugbank.com/drugs/DB17601InvestigationalDeveloped by Vericel Corporation, it is being investigated for cardiomyopathy.
Fluorofuranylnorprogesterone F-18
go.drugbank.com/drugs/DB15282InvestigationalFluorofuranylnorprogesterone F-18 is under investigation in clinical trial NCT02455453 (Assessment of Functional Status of Estrogen Receptors in Breast Cancer by Positron Emission Tomography).
Pentostatin
go.drugbank.com/drugs/DB00552ApprovedInvestigationalA potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosupp...
Synonyms: Co-vidarabineAGS-004
go.drugbank.com/drugs/DB05742InvestigationalNon-personalized HIV immunotherapies are unable to raise cytotoxic T lymphocytes against HIV antigens, fail to induce T cell memory, and, most importantly, do not provide antiviral protection against the … AGS-004 is a personalized RNA-loaded dendritic cellbased immunotherapy that is designed to stimulate the patient’s immune system to target and destroy the patient’s own unique viral burden.
CMLVAX100
go.drugbank.com/drugs/DB05164ExperimentalIt is developed by Breakthrough Therapeutics and has completed phase I of its clinical trial.